The objective of our study was to examine the changes in coagulation parameters and inflammatory reaction over the course of 15 days in patients with severe sepsis. We tried to identify mechanisms by which sepsis-induced pathophysiological changes may influence the effectiveness of subcutaneously (SC) administered enoxaparin 40 mg once daily.
Introduction
Systemic inflammatory response syndrome is associated with the activation of a range of defense mechanisms, including changes in hemostasis. Inflammation promotes coagulation by leading to intravascular tissue factor expression, eliciting the expression of leukocyte adhesion molecules on the intravascular cell surfaces, and downregulating the fibrinolytic and anticoagulant pathways. 1 Thrombin, in turn, can promote inflammatory responses. 2 As a result, patients with sepsis have an increased risk of thromboembolic complications. 3 Contemporary guidelines 4 therefore recommend that lowmolecular-weight heparins (LMWHs) or unfractionated heparin (UFH) should be administered subcutaneously (SC) as prophylaxis of deep vein thrombosis (DVT), unless contraindicated. However, several studies reported a lower inhibition of activated factor Xa (FXa) following SC administration of LMWH to critically ill patients compared to that achieved in healthy volunteers. [5] [6] [7] [8] [9] Sepsis and septic shock are accompanied by profound changes in the organism that might interfere with the effectiveness of SC administrated LMWHs in critically ill patients. Drug absorption following SC administration may be reduced because of a decreased perfusion due to use of vasopressors or body wall edema. Changes in plasma protein concentrations may also affect drug distribution-the increase in plasma concentration of an acute-phase reactant may result in a decreased distribution volume but may also lead to increased nonspecific binding. In contrast, renal failure, which often accompanies sepsis and septic shock, may result in accumulation of the drug. 10 The objective of this study was to monitor how the selected parameters of coagulation and inflammatory reaction change during the course of a 15-day follow-up in patients with severe sepsis and whether FXa inhibition in the arbitrarily established range of 0.2 to 0.4 IU/mL 11, 12 was reached in these patients after the prophylactic dose of SC administrated LMWH. Based on the results of the MEDENOX (A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely III Medical Patients) study, 13 LMWH enoxaparin at a dose of 40 mg/24 h SC is recommended from the range of available LMWH products for prophylaxis of DVT in patients with an acute infection and was also used in this study. Another objective of our study was to find out whether the level of FXa inhibition is correlated with variables of hemostasis: activated partial thromboplastin time (aPTT), prothrombin time (PT), level of fibrinogen, antithrombin (AT) and protein C (PC) activity, concentration of D-dimer, fragment 1.2 (F1.2, fragments of prothrombin), or inflammation: ''positive'' (Creactive protein [CRP] , orosomucoid [synonymum a1-acid glycoprotein], a-1-antitrypsin) and ''negative'' (transferrin and prealbumin) acute-phase protein 14 and interleukin 6 (IL-6) levels. In addition, we studied whether the FXa inhibition was influenced by body mass index (BMI), arterial pressure (mean, systolic, and diastolic arterial pressure), or creatinine clearance.
Materials and Methods

Selection of Patients
A total of 16 patients (8 men, 8 women, aged 35 to 83), who were admitted to the intensive care unit (ICU) of the 1st Surgical Department at the General University Hospital in Prague with a diagnosis of severe sepsis, were enrolled in the study. Criteria for study inclusion were fulfilling the criteria of severe sepsis according to the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference, 15 indication for thromboembolic prophylaxis, 16 and age >18 years. Exclusion criteria were any contraindication for anticoagulation with heparins, treatment with anticoagulatory or antiplatelet drugs, continuous venovenous hemofiltration, or other extracorporeal therapies. Monitoring and blood sample collections were carried out at days 1, 2, 3, 6, 9, 12, and 15 of hospitalization, always 4 hours (+15 minutes) after the administration of enoxaparin. To avoid the contamination of the blood samples with heparin, blood samples were collected directly from venous punctures, not from a line with heparin flush. The clinical condition was evaluated by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. 17 The protocol was approved by the Institutional Ethics Committee. Written informed consent was required, if possible, from all patients, or otherwise from the closest family members.
Treatment and Prophylaxis of DVT
The patients were treated according to the Surviving Sepsis Campaign guidelines, 16 and enoxaparin (Clexane injection solution 0.4 mL, Aventis, France) at a single SC dose of 40 mg/24 hours was used for DVT prophylaxis in all patients. Enoxaparin was administered into the skin fold of the abdominal wall at the time of admission to ICU and then everyday between 6 and 7 AM. Citrated plasma was also used to determine the concentrations of human prothrombin fragment F1.2 (ELISA Enzygnost F1.2 Monoclonal kit, Dade Behring). ELISA tests were measured using the MRX Microplate Reader (Dynatech Laboratories, Chantilly, Virginia). Acute-phase proteins CRP, orosomucoid, a-1-antitrypsin, transferrin, and prealbumin concentrations were determined by the nephelometric method with CardioPhase hsCRP Reagent and N Antisera to human a1-acid glycoprotein, human a1-antitrypsin, human transferrin and human prealbumin reagents (all from Dade Behring) using a Behring Nephelometer (BN) II analyzer (Dade Behring).
Laboratory Methods
Serum and plasma samples for the ELISA assays were stored for a maximum of 2 months at -80 C until determination. IL-6 levels were determined in serum samples by Human Cytokine Lincoplex Kit (Millipore, St Charles, Missouri) using a Luminex 200 analyzer (Luminex Corporation, Austin, Texas). Creatinine was determined by the Jaffe colorimetric method. 18 The normal laboratory values of these tests are summarized in Table 1 . The intraassay and interassay coefficients of variance (CVs) are less than 10% for all, with the exception of IL-6, where the mean intraassay and interassay CVs are 6.6% and 12.6%, respectively.
Statistical Methods
The statistical program SAS version 9.1 (SAS Institute Inc, Cary, North Carolina) was used for statistical analysis.
Descriptive statistical data were determined and 1-way repeated measures analysis of variance with the post hoc Holm-Sidak test was used to compare differences in time for normal distribution, while the Friedman repeated measures analysis of variance on ranks with the post hoc Tukey test was used for data with nonnormal distribution. To estimate the relation between anti-FXa and selected variables, we used multiple regression, taking participants out as a factor. This method is recommended 19, 20 to analyze data with more than 1 observation per participant (repeated measures data). Using this method, we get a ''within-participant'' correlation coefficient that estimates whether changes in 1 variable in the same participant are paralleled by changes in the other variable. The level of statistical significance was determined at P .05 for each test.
Results
The baseline APACHE II score in all patients was < 25. The mean baseline creatinine level was 136.2 + 79.9 mmol/L. Ileofemoral DVT on the left side was diagnosed in 1 patient on day 6 of the follow-up using computer tomography. In 2 patients, the course of sepsis was complicated by bleeding, and a surgical wound was identified as the source of bleeding in both these patients. The bleeding occurred on day 1 and day 6, respectively. This did not require the discontinuation of enoxaparin administration.
Neither heparin-induced thrombocytopenia nor an allergic reaction to enoxaparin was recorded in any patients. No patient met the criteria of overt disseminated intravascular coagulation (DIC) according to the International Society on Thrombosis and Haemostasis (ISTH) DIC score 21 at the time of ICU admission. No patient had severe thrombocytopenia (lower than 50 Â 10 9 /L); 1 patient had mild thrombocytopenia (50-150 Â 10 9 /L) at the time of admission. The abdominal cavity was defined as the source of infection in all patients enrolled; 10 of them had generalized peritonitis at the time of admission. Seven patients had a proven extraintestinal locus of infection in addition (6 of them had bronchopneumonia, 5 urinary tract infection, 1 mediastinitis). One patient had positive hemoculture. All patients underwent a major surgical intervention to control the site of the infection before or on the day of the admission to the ICU. Eight patients received hemodynamic support with catecholamines at least for 1 day. All patients had mechanical ventilation; the mean length of the artificial ventilation was 13.8 days. Further demographic data on patients 22 and their associated diseases are summarized in Table 2 .
Findings from the descriptive analysis of the variables of inflammatory reaction and coagulation on days 1, 2, 3, 6, 9, 12, and 15 and their changes during the observation period are shown in Table 1 .
Determination of the FXa inhibition (sample collection 4 hours after the prophylactic dose of enoxaparin 40 mg SC) was carried out a total of 109 times in all observed patients over the course of treatment at the ICU. Three measurements were missing, for the reason that 1 patient was treated with UFH intravenously (IV) after DVT was diagnosed.
The mean FXa inhibition from these measurements was 0.169 IU/mL (+0.173), the prophylactic range of 0.2 to 0.4 IU/mL was reached in 22 cases (20% of the total number of examinations), while 74 times (68%) FXa inhibition decreased under the prophylactic range, 13 times (12%) FXa inhibition by contrast increased > 0.4 IU/mL. All patients had at least 1 subprophylactic level of FXa inhibition; 5 patients (31%) had persistently subprophylactic levels of FXa inhibition throughout the whole study period. A graphic depiction of the values of FXa inhibition during the follow-up study is shown in the graph (Figure 1) . A gradual increase in the FXa inhibition values was observed during the follow-up period. Between days 9 and 15, the mean values were within the prophylactic range.
When examining the entire 15-day period, the level of FXa inhibition positively correlates with the level of AT activity (r ¼ .42; P < .001; Figure 2 ) and PC activity (r ¼ .45; P < .001; Figure 3 ). Positive correlation was also found between the level of FXa inhibition and the prealbumin levels (r ¼ .46; P < .001). No significant correlation between the level of FXa inhibition and a-1-antitrypsin concentrations was found in the whole study group. Such negative correlation (r ¼ 
Discussion
In the study, we followed the dynamics of changes in the markers of inflammatory and coagulation response in patients with severe sepsis at 9 time points within 15 days after admission to the ICU. To date, only those changes that occurred in the ''early'' phase of the body's response to sepsis, that is, during the first 3 days, 23 or up to 7 days, 24 were relatively well known. A similar course of changes in the inflammatory reaction and coagulation during the first week was also recorded in our patients. The maximum inflammatory (level of IL-6, a-1-antitrypsin, CRP, orosomucoid) and procoagulation response (increased levels of F1.2 fragments and D-dimer) was found during the first 3 days, that is, at the initial phase of sepsis. Furthermore, the concentration of positive acute-phase proteins decreased, with a significant difference versus the baseline on day 12 and day 15 of the follow-up (P < .05); but even on day 15, the concentrations of these variables were still higher than our laboratory norm. In addition to this, we recorded an opposite course of the change in the concentration of the negative protein phase, transferrin and prealbumin, which suggests an incipient catabolism, 25, 26 which gradually normalized at the end of the follow-up period. The initially low activity of natural coagulation inhibitors (AT and PC) observed is a typical finding for sepsis and was also observed in the Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study. 24 Concerning DVT prophylaxis, the administration of SC UFH or preferably LMWH 4 is recommended in patients with sepsis. Thanks to their pharmacokinetic and pharmacodynamic properties, LMWHs have better predictable effects than UFH and, therefore, no monitoring of their anticoagulation effects is generally needed. 22 However, the results of previous studies showed that an effective DVT prophylaxis is difficult to achieve. [5] [6] [7] [8] [9] In our study of patients with severe sepsis, the Even though the range of 0.2 to 0.4 anti-Xa U/mL is widely used, 11, 12 we are aware that it may be controversial, as this range has never been validated in any major trials. Therefore, we tried to compare anti-FXa activities of septic patients with results of FXa inhibitions reached after the same daily dose of enoxaparin 40 mg SC in another group of patients with high DVT risk (nonseptic patients, who underwent a hip fracture surgery). We found that FXa inhibition levels in the septic patient group were significantly lower (P < .05) compared to the nonseptic patient group (compared on day 2 of hospitalization in the ICU in septic patients versus day 2 after surgery in the control group; and day 6 of hospitalization in the ICU in septic patients versus day 7 after surgery in the control group). Mean FXa inhibition levels in the group of nonseptic patients after hip fracture surgery (n ¼ 16) were 0.38 IU/mL (+SD 0.16) on day 2 after surgery and 0.4 IU/mL (+SD 0.14) on day 7 after surgery (Kudrnova Z., Kvasnicka J. 2008). Determination of the FXa inhibition (sample collection 4 hours after the prophylactic dose of enoxaparin 40 mg SC) was carried out with the same anti-FXa assay (chromogenic factor Xa inhibition assay Coamatic Heparin).
We suppose that our findings can be caused by a lower activity of AT in patients with sepsis, 6 which was also observed in our study, because enoxaparin requires AT for its anticoagulation activity. 22 We confirmed this relation by the positive correlation between the AT activity and FXa inhibition. Decreased AT activity (<70%) was significantly associated with an insufficient FXa (mean 0.12 IU/mL); in contrast, the group with normal AT activity reached average FXa inhibition (mean 0.24 IU/mL) within the required range. In our study, correlation was also found between FXa inhibition and activity of the natural inhibitor of coagulation PC and levels of FXa inhibition. The positive correlation between PC levels and enoxaparin level (reported in anti-FXa activity IU/mL) may be explained by the protective effect of LMWH on the depletion of natural inhibitor of coagulation PC.
Because the biological availability of UFH can be influenced partially by its binding to plasma proteins, as already demonstrated for acute-phase proteins such as orosomucoid and/or a-1-antitrypsin, 27 it can be expected that a similar effect can also occur for LMWH, which is manufactured by fractionation of UFH. 22 Whether the bioavailability of LMWH decreases during an acute-phase response, as can be found in critically ill patients, is unknown. 7 This effect may occur in patients with sepsis who have elevated levels of acute-phase proteins during the inflammatory reaction. We found a negative correlation between the FXa inhibition and a-1-antitrypsin concentrations (r ¼ -.33; P ¼ .01) in the group of patients with a-1-antitrypsin concentrations !2.2 g/L. However, the influence of orosomucoid, another acute-phase protein, was not demonstrated by the test we used, because its level remained similarly elevated during almost the entire follow-up period.
Another factor influencing the anticoagulation effect of LMWH is the administration of vasopressors, which leads to a decrease in the peripheral tissue perfusion and insufficient absorption of the SC applied drug. However, this hypothesis was not confirmed in our study.
We also tried to test the hypothesis that low creatinine clearance (counted using the MDRD formula) may lead to bioaccumulation of LMWH and can therefore cause an increase in FXa-inhibition levels in the later samples in the individuals with renal impairment. However, we found no statistically significant correlation between initial creatinine clearance levels and later FXa-inhibitions.
Limitations
Our study was not designed to systematically detect the clinical end points such as venous thromboembolism or hemorrhagic complications during prophylaxis with enoxaparin. Factor Xa inhibition may be a marker of LMWH activity, which may or may not be causally related to the clinical outcome, [28] [29] [30] because there exist other mechanisms by which LMWHs influence hemostasis, for example tissue factor pathway inhibitor (TFPI) activity. 22 The measurement of Xa inhibition with the used Coamatic kit allows detecting that low AT levels may contribute to low functional levels of FXa inhibition. However, to assess whether LMWH levels are lower than expected due to nonspecific binding to plasma proteins, other anti-Xa level assays using AT supply will need to be performed on the samples. We did not take into consideration all the potential factors that could have induced significant changes in coagulation: type of surgery undergone and medication (eg, antibiotherapy, corticosteroids).
Conclusion
We demonstrated that prophylaxis of DVT using a standard enoxaparin dose of 40 mg SC once daily failed to reach the arbitrarily established FXa inhibition (0.2-0.4 IU/mL) in 80% cases of our patients with severe sepsis. The majority of patients do not reach appropriate levels of FXa inhibition, particularly in the early phases. This indicates the need for monitoring FXa inhibitory activity and adjusting the dosage to reach the prophylactic range. However, increasing doses of LMWH in these patients may lead to increased risk of bleeding complications. Therefore, such a strategy should be tested in a larger cohort of patients with sepsis.
The variability and suboptimal level of anticoagulation is likely related to consumption of AT and the level of coagulation activation. This opens the possibility of an individual substitution of AT. So far it is not known whether septic patients may also profit from usage of new antithrombotic agents (direct FXa or thrombin inhibitors), which do not need AT as a cofactor. laboratory staff of Central Hematological Laboratories for their excellent assistance in the study.
